NCT05320380 - A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | Biotech Hunter

Timeline

Start Date

August 1, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions

Recurrent Acute Myeloid LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent T Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRefractory T Acute Lymphoblastic Leukemia

Interventions

DRUG

Anti-CD123 ADC IMGN632

Given IV

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration/biopsy

DRUG

Cytarabine

Given IT and IV

DRUG

Fludarabine Phosphate

Given IV

DRUG

Hydrocortisone Sodium Succinate

Given IT

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

DRUG

Methotrexate

Given IT

DRUG

Prednisolone

Given IT